Saiz Juan-Carlos, Martín-Acebes Miguel A
Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Madrid, Spain
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00411-17. Print 2017 Jun.
Zika virus (ZIKV), a flavivirus transmitted by mosquitoes, was an almost neglected pathogen until its introduction in the Americas in 2015 and its subsequent explosive spread throughout the continent, where it has infected millions of people. The virus has caused social and sanitary alarm, mainly due to its association with severe neurological disorders (Guillain-Barré syndrome and microcephaly in fetuses and newborns). Nowadays, no specific antiviral therapy against ZIKV is available. However, during the past months, a great effort has been made to search for antiviral candidates using different approaches and methodologies, ranging from testing specific compounds with known antiviral activity to the screening of libraries with hundreds of bioactive molecules. The identified antiviral candidates include drugs targeting viral components as well as cellular ones. Here, an updated review of what has been done in this line is presented.
寨卡病毒（ZIKV）是一种由蚊子传播的黄病毒，在2015年传入美洲并随后在整个大陆爆发性传播之前，它几乎是一种被忽视的病原体，在美洲已感染了数百万人。该病毒引发了社会和卫生警报，主要是因为它与严重的神经疾病（格林-巴利综合征以及胎儿和新生儿小头畸形）有关。目前，尚无针对寨卡病毒的特异性抗病毒疗法。然而，在过去几个月里，人们付出了巨大努力，采用不同的方法和手段寻找抗病毒候选药物，从测试具有已知抗病毒活性的特定化合物到筛选含有数百种生物活性分子的文库。已鉴定出的抗病毒候选药物包括针对病毒成分以及细胞成分的药物。在此，对这方面已开展的工作进行最新综述。
